



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



M4284

Cat. No.:	HY-120568
CAS No.:	1373346-85-0
Molecular Formula:	C ₂₃ H ₂₈ N ₂ O ₈
Molecular Weight:	460.48
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (271.46 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.1716 mL	10.8582 mL	21.7165 mL
		5 mM		0.4343 mL	2.1716 mL	4.3433 mL
		10 mM		0.2172 mL	1.0858 mL	2.1716 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (13.57 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6.25 mg/mL (13.57 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	M4284 is a selective and orally active biphenyl mannoside FimH antagonist. M4284 has activities against different UPEC (Urinary tract infections (UTI) caused by uropathogenic E. coli) strains in different host genetic backgrounds and gut microbial community contexts ^[1] .
IC ₅₀ & Target	IC ₅₀ : FimH ^[1]
In Vivo	M4284 (oral administration; 100 mg/kg; 3 doses) can reduces UTI89 levels in the gut and urinary tracts of mice that are concurrently colonized with UTI89 in the gut and bladder. And treating mice with additional M4284 doses further reduces the UTI89 population and the number of UPEC is lower in M4284-treated mice after termination of treatment ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C3H/HeN mice ^[1] .
Dosage:	100 mg/kg
Administration:	Oral administration; a single dose.
Result:	Had activities against different UPEC strains in different host genetic backgrounds and gut microbial community contexts.

REFERENCES

[1]. Schaeffer EM, et al. Selective Depletion of Uropathogenic E. coli from the Gut by a FimH Antagonist. *Selectiv J Urol*. 2018 Apr;199(4):874-875.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA